Production (Stage)
Design Therapeutics, Inc.
DSGN
$3.84
-$0.07-1.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 41.00M | 35.42M | 34.28M | 35.66M | 35.69M |
| Gross Profit | -41.00M | -35.42M | -34.28M | -35.66M | -35.69M |
| SG&A Expenses | 18.48M | 18.03M | 17.61M | 18.80M | 19.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.40M | 62.38M | 60.81M | 63.39M | 70.94M |
| Operating Income | -68.40M | -62.38M | -60.81M | -63.39M | -70.94M |
| Income Before Tax | -56.20M | -49.59M | -47.78M | -50.53M | -58.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.20 | -49.59 | -47.78 | -50.53 | -58.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.20M | -49.59M | -47.78M | -50.53M | -58.67M |
| EBIT | -68.40M | -62.38M | -60.81M | -63.39M | -70.94M |
| EBITDA | -67.79M | -61.79M | -60.23M | -62.82M | -70.39M |
| EPS Basic | -0.99 | -0.88 | -0.85 | -0.90 | -1.05 |
| Normalized Basic EPS | -0.62 | -0.55 | -0.53 | -0.56 | -0.65 |
| EPS Diluted | -0.99 | -0.88 | -0.85 | -0.90 | -1.05 |
| Normalized Diluted EPS | -0.62 | -0.55 | -0.53 | -0.56 | -0.65 |
| Average Basic Shares Outstanding | 226.62M | 226.35M | 225.76M | 225.12M | 224.52M |
| Average Diluted Shares Outstanding | 226.62M | 226.35M | 225.76M | 225.12M | 224.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |